Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy

International Journal of Urology

Volumn 18, Issue 3, 2011, Pages 200-205

  Ochiai, Atsushi ^a   Okihara, Koji ^a   Kamoi, Kazumi ^a   Iwata, Tsuyoshi ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a   Fors, Zephyr ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Gen Probe Incorporated   (United States)

Author keywords

Japanese men; PCA3 urine assay; Prostate cancer

Indexed keywords

MESSENGER RNA; PROSTATE PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR PROTEIN;

ADULT; ARTICLE; ASIAN; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79951785368     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02711.x     Document Type: Article

References (15)

1. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl. Cancer Inst. 2009; 101: 1325-9.
2. Oestering JE, Jacobsen SJ, Chute CG etal. Serum Prostate-specific antigen in a community-based population of healthy men. Establishment of age specific reference ranges. JAMA 1993; 270: 860-4.
3. Babaian RJ, Kojima M, Ramirez EI etal. Comparison analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J. Urol. 1996; 156: 432-7.
4. Catalona WJ, Southwick PC, Slawin KW etal. Comparison of percent free PSA, PSA density and age specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60.
5. Stamey TA, Caldwell M, McNeal JE etal. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20years? J. Urol. 2004; 172: 1297-301.
6. Ochiai A, Troncoso P, Babaian RJ. The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J. Urol. 2007; 177: 903-6.
7. Bussemakers MJG, Bokhoven AV, Verhaegh GW etal. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59: 5975-9.
8. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003; 44: 8-16.
9. Tinzl M, Marberger M, Horvath S etal. DD3PCA3RNA analysis in urine - a new perspective for detecting prostate cancer. Eur. Urol. 2004; 46: 182-7.
10. Groskopf J, Aubin SMJ, Deras IL etal. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006; 52: 1089-95.
11. Deras IL, Aubin SM, Blasé A etal. PCA: A molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008; 179: 1587-92.
12. Haese A, Taille A, Poppel H etal. Clinical utility of the PCA3 urine assay in European men scheduled for repeated biopsy. Eur. Urol. 2008; 54: 1081-8.
13. Marks LS, Fradet Y, Deras IL etal. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5.
14. Shappell S, Fulmer J, Arguello D etal. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009; 73: 363-8.
15. Nakanishi H, Groskopf J, Fritsche HA etal. PCA3 molecular urine assay correlates with prostate tumor volume: Implication in selecting candidate for active surveillance. J. Urol. 2008; 179: 1804-10.